Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis

Abstract Background This study aimed to analyze the effects of ruxolitinib on children with secondary hemophagocytic lymphohistiocytosis (HLH). Methods Eleven pediatric patients diagnosed with HLH and treated with ruxolitinib (ruxolitinib group: group R) between November 2017 and August 2018 were re...

Full description

Bibliographic Details
Main Authors: Ying Chi, Rong Liu, Zhi-xuan Zhou, Xiao-dong Shi, Yu-chuan Ding, Jian-guo Li
Format: Article
Language:English
Published: BMC 2021-04-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Ruxolitinib
Hemophagocytic lymphohistiocytosis
Janus kinase inhibitor
Children
Online Access:https://doi.org/10.1186/s12969-021-00534-0

Internet

https://doi.org/10.1186/s12969-021-00534-0

Similar Items